NEW YORK (GenomeWeb News) – Thermo Fisher Scientific's first-quarter revenues rose 4 percent year over year, the company reported today, beating Wall Street expectations on the top and bottom lines.
Registering provides access to this and other free content.
Already have an account?Login Now.
The Guardian discusses whether big science projects are worth the loss of resources available for other scientific pursuits.
An NEJM update from the ClinVar team highlights the difficulties of interpreting genetic variants.
In Nature this week: genomic analysis of high-grade serous ovarian cancer, and more.
The new Riken president outlines some of his plans for the institute.